financetom
Business
financetom
/
Business
/
Stellantis output in Italy down 10% in Q1, trade union says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Stellantis output in Italy down 10% in Q1, trade union says
Apr 5, 2024 3:24 AM

MILAN (Reuters) - Production of passenger cars and vans at Stellantis' Italian plants fell 9.8% year-on-year in the first three months of this year to 170,415 units, the FIM-CISL union said on Friday.

"This takes Stellantis further away from the one million output target" the automaker is discussing with the Italian government, the head of FIM-CISL Ferdinando Uliano said, presenting a quarterly report on Stellantis' production levels.

FIM-CISL projects a full-year output of 630,000 vehicles in 2024, down from 751,000 last year, based on first-quarter data and assuming auto purchase incentives announced by the government do not reverse the ongoing trend.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Switzerland removes 12 people from Russia sanctions list
Switzerland removes 12 people from Russia sanctions list
Mar 22, 2024
March 22 (Reuters) - Switzerland has removed 12 people from its Russia sanctions list over the war in Ukraine, the State Secretariat for Economic Affairs (SECO) said on Friday. Among them is Arkady Volozh, a co-founder of Russian internet giant Yandex ( YNDX ), who recently cut ties with the Russian business and condemned the invasion of Ukraine. He was...
Gilead Sciences Completes $4.3 Billion Cymabay Acquisition
Gilead Sciences Completes $4.3 Billion Cymabay Acquisition
Mar 22, 2024
09:56 AM EDT, 03/22/2024 (MT Newswires) -- Gilead Sciences ( GILD ) said Friday it has completed its $4.3 billion acquisition of CymaBay Therapeutics ( CBAY ). The company said CymaBay's lead product candidate for primary biliary cholangitis, seladelpar, 'complements' its existing liver portfolio. Price: 72.95, Change: -0.14, Percent Change: -0.19 ...
Brady Insider Sold Shares Worth $477,100, According to a Recent SEC Filing
Brady Insider Sold Shares Worth $477,100, According to a Recent SEC Filing
Mar 22, 2024
10:01 AM EDT, 03/22/2024 (MT Newswires) -- Elizabeth P Bruno, Director, on March 20, 2024, sold 8,322 shares in Brady (BRC) for $477,100. Following the Form 4 filing with the SEC, Bruno has control over a total of 333,593 shares of the company, with 333,593 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/746598/000074659824000016/xslF345X03/wk-form4_1711111874.xml Price: 58.41, Change: -0.18, Percent Change: -0.31 ...
Novartis Says EU Regulator Panel Recommends Marketing Authorization for Fabhalta to Treat Blood Disorder
Novartis Says EU Regulator Panel Recommends Marketing Authorization for Fabhalta to Treat Blood Disorder
Mar 22, 2024
09:55 AM EDT, 03/22/2024 (MT Newswires) -- Novartis ( NVS ) said Friday the European Medicines Agency's Committee for Medicinal Products for Human Use is recommending a marketing authorization for Fabhalta to treat people with paroxysmal nocturnal hemoglobinuria, a rare blood disorder. The committee's positive opinion was based on results from a late-stage trial showing superior hemoglobin improvement in the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved